Apheresis · Blood Filtration · Inflammation
One of the most underappreciated dimensions of chronic Lyme disease is what accumulates in the bloodstream over months and years of sustained immune activation. Pro-inflammatory cytokines, immune complexes formed from antibody-antigen binding, bacterial debris, and metabolic byproducts of chronic inflammation — these substances circulate continuously, signaling danger to every tissue they reach and perpetuating the immune dysregulation that drives symptoms.
Therapeutic apheresis directly addresses this accumulated burden. By filtering the blood through a specialized separation circuit, it removes specific classes of inflammatory molecules that other treatments cannot reach — creating a biochemical clean slate that significantly changes the internal environment chronic Lyme patients are working against.
Therapeutic apheresis is not a generic filtration process. The separation technology used in our protocol is calibrated to target the specific molecular categories most implicated in chronic Lyme inflammatory burden.
Therapeutic apheresis uses an extracorporeal circuit — meaning blood is temporarily routed outside the body through a separation device, processed, and returned. The procedure is performed in a clinical setting with continuous monitoring and takes several hours to complete depending on blood volume and treatment goals.
Blood is drawn through an IV access line and routed into the apheresis circuit. Flow rates are controlled and monitored throughout.
The circuit separates plasma — the liquid component of blood carrying inflammatory molecules — from the cellular components (red cells, platelets, white cells) which are preserved.
Separated plasma passes through the filtration columns where target inflammatory molecules are selectively removed. The specific filtration technology depends on the patient's profile and treatment goals.
Processed plasma is reconstituted with replacement fluid and returned to the patient along with the preserved cellular components. The patient's total blood volume is processed over the session.
An important distinction: Therapeutic apheresis is not dialysis. Dialysis removes small waste molecules — creatinine, urea — from patients with kidney failure. Apheresis targets much larger molecular species — immune complexes, cytokines, autoantibodies — that kidneys cannot filter and that are specifically responsible for the inflammatory burden in chronic Lyme disease.
The response to apheresis varies between patients, and expectations should be calibrated accordingly. Some patients notice relatively prompt changes — reduced joint swelling, decreased inflammatory pain, improved mental clarity — in the days following treatment. Others experience a more gradual shift over weeks as the reduced inflammatory burden allows downstream processes to begin normalizing.
A proportion of patients experience a temporary worsening of symptoms immediately after apheresis, as the redistribution of inflammatory molecules and the shift in immune dynamics creates a brief period of adjustment. This typically resolves within 24 to 72 hours and does not indicate treatment failure.
What apheresis reliably achieves — measurably and consistently — is a reduction in the circulating inflammatory burden. Whether and how rapidly that reduction translates to symptom improvement depends on the patient's underlying biology, disease duration, and what follows the apheresis in their treatment protocol.
Apheresis is most powerful when it is positioned correctly within a coordinated treatment sequence rather than used as a standalone intervention. The reason is architectural: removing inflammatory mediators from the bloodstream creates a window — a period in which the internal environment is significantly less hostile to subsequent interventions.
In our protocols, apheresis typically precedes Treg therapy. Reintroducing regulatory T cells into a bloodstream still saturated with IL-6, TNF-alpha, and immune complexes means those cells immediately face the hostile conditions that destabilized the patient's native Tregs. Apheresis first clears that toxic environment — giving the reinfused cells a significantly better chance of establishing functional regulatory activity.
When combined with Systemic Perfusion Hyperthermia, the sequencing works similarly: hyperthermia mobilizes inflammatory debris and bacterial components into circulation, and apheresis then removes what has been mobilized — a coordinated one-two combination that targets both active pathogen burden and accumulated inflammatory load in a single treatment arc.
Our clinical team will evaluate your inflammatory profile and treatment history to determine whether apheresis is appropriate and how it fits within your protocol.
Check My Eligibility